Today's Trend
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) — Shares moved lower today despite fresh analyst model upgrades. HC Wainwright raised near-term EPS estimates across Q1–Q4 2026 and out-year forecasts (including a small FY2030 profit projection) and kept a "Buy" rating with a $19 target. Below are the key investor-relevant points explaining today's action.
- HC Wainwright raised multiple quarterly and annual EPS estimates (Q1–Q4 2026, FY2026–FY2030), narrowing projected losses and moving FY2030 to a small positive EPS; the firm reiterated a "Buy" rating and a $19 price target. HC Wainwright note
- The EPS upgrades are incremental (small changes in cents per quarter/year) — they improve the trajectory but do not materially change near-term cash-burn or clinical-development risk; consensus for FY2026 remains a sizeable loss.
- Shares are trading down today amid low liquidity (volume below the three‑month average), below both the 50‑day and 200‑day moving averages, and following recent quarterly results that showed continued losses — all factors that can trigger short‑term selling/pressure in a small‑cap biotech with a high beta.
Bottom line for investors: the analyst action is constructive for ACRV's long‑term narrative (a buy rating and a distant $19 target), but the upgrades are modest and the company still faces near‑term losses, thin trading, and technical pressure — which helps explain why the stock fell today despite the positive analyst revisions.